Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of mechanisms and biomarkers of toxicity from targeted anticancer therapies
NL-OMON37674Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ipilimumab and vemurafenib in cancer (5 arms), sponsored by Vrije University Medical Center. Primary endpoint: Biological impact of targeted therapy in normal tissue related to toxicity. Started Mar 2013; status: active, not recruiting.
02
Drugs
ipilimumabvemurafenib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON37674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37674.